Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of May 14, 2025 • 6:31 PM ET

Date/Time Source News Release
02/27/2025 08:00 AM EST GlobeNewswire Fusion Fuel Appoints Luisa Ingargiola to Board of Directors
08/15/2024 08:30 AM EDT GlobeNewswire BioCorRx Reports Business Update for the Second Quarter of 2024
04/03/2024 08:30 AM EDT GlobeNewswire BioCorRx Pharmaceuticals Inc. Awarded New Patent for Novel Compound to Treat Pain, Depression, and Schizophrenia
04/02/2024 08:30 AM EDT GlobeNewswire BioCorRx Reports Business Update for 2023
02/28/2024 10:49 AM EST GlobeNewswire BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
02/08/2024 09:52 AM EST GlobeNewswire BioCorRx Pharmaceuticals Inc. Appoints Neuroscientist Dr. Kate DeVarney to the Board of Directors
01/09/2024 08:30 AM EST GlobeNewswire BioCorRx Appoints Renowned Investment and Capital Markets Executive Louis Lucido as President
08/15/2023 09:00 AM EDT GlobeNewswire BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
08/14/2023 04:34 PM EDT GlobeNewswire BioCorRx Reports Business Update for the Second Quarter of 2023
07/18/2023 08:30 AM EDT GlobeNewswire BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
Page

Additional News

As of May 14, 2025 • 6:31 PM ET

Date/Time Source News Release
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.